2006:
February: The Japan Ministry of Health directed antidepressant manufacturers to add warnings of suicide risk when taking the drugs.
一月：日本厚生省（衛生署）指示抗憂鬱劑製造商加註警語：服用這些藥物有自殺的危險性。
February: The British Medicine and Healthcare Products Regulatory Agency reported the antidepressant Strattera (also used for “ADHD”) was associated with seizures and a potentially dangerous lengthening of time between heartbeats.
一月：英國醫藥及保健產品管理局報告抗憂鬱劑Strattera(也用來治療ADHD，即注意力缺乏過動症)和癲癇有關以及會延長心跳間隔的潛在危險。
May: Health Canada issued new warnings of rare heart risks for all stimulants, such as Ritalin and l, prescribed for “ADHD,” including the risk of sudden death. In August, the FDA ordered a similar warning be added to stimulant drug packaging. UK followed in November.
五月：加拿大健康局針對所有的興奮劑公告罕見的心臟危險性的新公告，像是利他能（Ritalin）, Adderal等等，也包含猝死的危險。八月時，美國食品藥物管理局要求類似的警語要加在藥物包裝上。英國在十一月也跟進。
2007:
March: New Zealand urged health professionals to monitor patients on the antipsychotic drug Clozapine after a review found five people had died.
三月：經過一項回顧報告中有五個人死亡，紐西蘭力勸健康專業人士監控抗精神藥物Clozapine的使用。
May: The German Drug Regulatory Agency (BfArM) warned that the antidepressant Paroxetine (Paxil) could increase the risk of cardiac malformation in newborns when taken during pregnancy.
五月：德國藥物管理局警告抗憂鬱劑克憂果（Paroxetine,Paxil）在懷孕時期服用，可能會增加新生兒的心臟畸形。
May 2: The FDA extended the age group for the black box warning about antidepressants inducing suicide from 18 to 24.
五月二日：美國食品藥物管理局把關於抗憂鬱劑引發自殺危險性的警語延伸到18至24歲的年齡層。
June: The Australian TGA reported a range of cardiac disorders (potentially fatal inflammation of the heart muscle) associated with the use of the antipsychotic, Clozapine.
六月：澳洲的TGA（治療性商品管理局）報導一種心臟疾病（心肌潛在性的致命發炎反應）是跟抗精神藥物Clozapine的使用有關。
September: The FDA reported a warning was added to the antipsychotic Haldol (haloperidol) about the potential risk of death and dangerous heart conditions observed in some patients.
九月：美國食品藥物管理局提出加在抗精神藥物好度Hadol(Haperidol)的警語：在某些病人觀察到潛在的致命性及危險的心臟症狀。
留言列表
